253
Views
2
CrossRef citations to date
0
Altmetric
Review

Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan

&
Pages 497-503 | Received 24 Nov 2015, Accepted 12 Feb 2016, Published online: 01 Mar 2016
 

ABSTRACT

Introduction: Drug approvals and patent protections are critical in drug lifecycle management (LCM) in order to maximize drug discovery investment returns.

Area covered: We analyzed drug LCM activities implemented by 10 top companies in Japan, focusing on drug approvals and patent term extensions.

Expert opinion: Foreign companies acquired numerous drug approvals primarily for new molecular entities (NMEs), while Japanese companies mainly obtained approvals for improved drugs including new indications, and intensively extended patent terms. Furthermore, we discovered three factors likely responsible for differences in drug LCM strategies of Japanese and foreign companies: research and development capacities for drugs, drug lags of foreign-origin NMEs, and cooperation between Research and Development Departments and Intellectual Property Departments.

Article highlights

  • Drug LCM approaches implemented by 10 top companies in Japan were divided into two clusters.

  • Foreign companies conducted NME-oriented LCM with enhanced R&D capacities.

  • Domestic companies intensively extended patent terms with additional drug approvals.

  • Drug lags of foreign-origin NMEs might prevent patent term extensions.

  • Lack of cooperation between R&D departments and intellectual property departments might cause opportunity loss.

This box summarizes key points contained in the article.

Declaration of Interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.